Pricing Log in Create free account
Saturday 17 October 2026 Export ATR’s income statement to Excel — free account

AptarGroup, Inc.

ATR Healthcare Medical Instruments & Supplies

AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024. In the quarter to June 2026, revenue grew 6.26%, EPS fell 18.3%, free cash flow fell 23.1% and total debt rose 66.4%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for ten.

124.51 0.25 +0.20%
Market cap
$7.9B
P/E
22.2×
Fwd P/E
21.0×
Dividend yield
1.54%
F-score
5/9
Altman Z
3.78
Beneish M
−2.48
Dividend safety
92/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 7.82
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 1 — 2 — — 2 2 — 4 1 —
Insider Ownership 1.95%

Capital & Financial Ratios $m

Market Cap 7,900.00
Revenue 3,933.24
Net Income 362.88
Free Cash Flow 314.58
Net Debt 1,170.39
Current Ratio 1.61 (at or above 1.5: strong)
Debt/Equity 0.52
P/E ratio 22.23
Fwd P/E 21.00
P/S ratio 2.01
P/B ratio 2.99
Past 5Y EPS Growth 12.91%
This Y EPS Growth (4.09%) (below 0%: weak)
Next Y EPS Growth 13.13%
Next Y revenue growth 5.26%
Next 5Y EPS Growth 6.49%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 2.6×; over the ten years it ranged from 2.1× in 2016 to 3.6× in 2021.
P/E against its own 10 years 7.63%
10-year low 10-year high
P/S against its own 10 years 8.66%
10-year low 10-year high
P/B against its own 10 years 4.02%
10-year low 10-year high
EV/Sales against its own 10 years 14.63%
10-year low 10-year high
EV/FCF against its own 10 years 19.79%
10-year low 10-year high

Dividends

Payout Ratio 0.35
Annual Dividend Rate 1.92
Annual Dividend Yield 1.54%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 1.94
0.48
0.48
0.48
2025 1.83
0.45
0.45
0.45
0.48
2024 1.72
0.41
0.41
0.45
0.45
2023 1.58
0.38
0.38
0.41
0.41
2022 1.52
0.38
0.38
0.38
0.38
2021 1.50
0.36
0.38
0.38
0.38
2020 1.44
0.36
0.36
0.36
0.36
2019 1.42
0.34
0.36
0.36
0.36
2018 1.32
0.32
0.32
0.34
0.34
2017 1.28
0.32
0.32
0.32
0.32
2016 1.22
0.30
0.30
0.30
0.32
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 224 226 410 197
Receivables 678 658 804 898
Inventory 513 462 538 580
Other — — — —
1,549 1,478 1,894 1,835
2023 2024 2025 Q'26
Payables 793 730 823 887
ST’ Debt 376 338 344 249
Other — — — —
1,251 1,068 1,166 1,137

Compound Annual Growth %

10y 5y 3y
Sales 5.01% 5.22% 4.37%
Cash Flow 5.82% (0.01%) 6.00%
Earnings 7.02% 12.91% 17.96%
Book Value 8.86% 7.73% 9.10%

Revenue $m

Mar Jun Sep Dec Year
’26 983 1,027 — — —
’25 887 966 961 963 3,777
’24 915 910 909 848 3,583
’23 860 896 893 838 3,487
’22 845 845 837 796 3,322
’21 777 811 825 814 3,227
’20 722 699 759 749 2,929
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 119 103 — — —
’25 83 126 178 184 570
’24 92 144 229 178 643
’23 98 84 173 220 575
’22 92 85 130 172 479
’21 72 103 84 104 363
’20 85 143 154 189 570
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 54 47 — — —
’25 23 61 116 98 298
’24 17 76 149 108 351
’23 20 9 97 135 262
’22 19 10 46 87 163
’21 9 34 4 13 61
’20 20 86 102 116 323
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 1.12 1.36 — — —
’25 1.17 1.67 1.92 1.13 5.89
’24 1.23 1.34 1.48 1.49 5.53
’23 0.82 1.24 1.26 0.93 4.25
’22 0.93 0.95 0.81 0.89 3.59
’21 1.24 0.81 0.70 0.85 3.61
’20 0.84 0.63 0.95 0.79 3.21
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 66.33 71.44 79.97 88.26 79.84 112.37 90.23 107.89 122.29 103.23

Analyst estimates 2026–2028

Powerpack
High 81.50 90.79 112.31 126.20 137.36 158.97 124.14 133.79 178.03 164.28
People
People Employees 12,700 13,200 14,100 14,000 13,000 13,000 13,500 13,800 13,500 14,000
Revenue/emp, $m 0.18 0.19 0.20 0.20 0.23 0.25 0.25 0.25 0.27 0.27
Income, $m
Income, $m Revenue 2,331 2,469 2,765 2,860 2,929 3,227 3,322 3,487 3,583 3,777
Gross margin, % 35.81 35.08 34.43 36.41 37.09 35.84 35.03 36.23 37.83 37.19
EBT 280 295 266 342 301 322 335 375 470 491
EBT margin, % 12.03 11.94 9.62 11.96 10.28 9.97 10.07 10.75 13.11 13.01
Net income 206 220 195 242 214 244 240 284 374 392
Depreciation 155 153 172 195 220 235 234 249 264 287
Per share, $
Per share, $ Revenue 37.11 39.55 44.28 44.98 45.47 49.15 50.80 53.15 54.01 57.46
Earnings 3.27 3.52 3.12 3.81 3.32 3.72 3.66 4.34 5.65 5.97
Cash flow 5.18 5.20 5.02 8.09 8.85 5.54 7.32 8.77 9.70 8.67
Capex (2.07) (2.48) (3.32) (3.82) (3.83) (4.61) (4.82) (4.77) (4.41) (4.14)
Free cash flow 3.11 2.73 1.70 4.27 5.02 0.93 2.49 4.00 5.29 4.53
Book value 18.70 21.01 22.79 24.73 28.73 30.22 31.62 35.38 37.48 40.86
Shares, m 63 62 62 64 64 66 65 66 66 66
Valuation, ×
Valuation, × P/E 22.33 24.65 30.15 30.35 41.23 32.84 30.21 28.31 27.81 20.43
P/S 1.97 2.20 2.12 2.57 3.01 2.49 2.17 2.31 2.91 2.12
P/B 3.91 4.14 4.13 4.68 4.76 4.05 3.49 3.47 4.19 2.99
EV/Sales 2.10 2.42 2.46 2.89 3.29 2.78 2.48 2.55 3.13 2.41
EV/FCF 25.05 35.63 64.01 30.40 29.81 164.11 51.31 33.93 31.99 30.50
Cash, $m
Cash, $m Operating cash flow 325 325 314 514 570 363 479 575 643 570
Capex (130) (155) (207) (243) (247) (303) (316) (313) (293) (272)
Free cash flow 196 170 106 272 323 61 163 262 351 298
Balance, $m
Balance, $m Working capital 727 1,142 642 608 589 376 513 298 410 727
Total debt 777 1,253 1,189 1,151 1,121 1,049 1,172 1,058 1,026 1,483
Net debt 311 540 927 909 820 926 1,030 834 800 1,073
Shareholders’ equity 1,174 1,312 1,423 1,572 1,851 1,985 2,068 2,321 2,486 2,686
Returns, %
Returns, % ROA 8.15 7.66 5.98 6.98 5.67 6.00 5.74 6.57 8.43 8.11
ROIC 13.20 10.91 7.61 9.36 7.94 7.46 7.65 8.00 9.44 8.33
ROE 17.69 17.70 14.24 16.17 12.51 12.73 11.81 12.96 15.58 15.19
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

AptarGroup, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RGEN Repligen Corporation $11.7B 234× 112× +11.93% (above 0%: growing) −65.38% (below 0%: shrinking) +27.10% (above 0%: growing) 53.91% 6.85% Compare
COO The Cooper Companies, Inc. $10.9B 19.8× 28.7× +0.56% (above 0%: growing) +357.14% (above 0%: growing) +65.96% (above 0%: growing) 66.77% 20.82% Compare
AVTR Avantor, Inc. $10.9B — (loss-making) 25.5× +0.53% (above 0%: growing) −33.33% (below 0%: shrinking) +12.66% (above 0%: growing) 31.73% 7.20% Compare
ALGN Align Technology, Inc. $10.6B 25.6× 20.7× +4.32% (above 0%: growing) −12.21% (below 0%: shrinking) +85.77% (above 0%: growing) 71.71% 14.58% Compare
ATR AptarGroup, Inc. $7.9B 22.2× 21.0× +6.26% (above 0%: growing) −18.34% (below 0%: shrinking) −23.07% (below 0%: shrinking) 35.61% 12.34%
BLCO Bausch + Lomb Corporation $6.0B — (loss-making) — (loss-making) +9.08% (above 0%: growing) n/m +251.85% (above 0%: growing) 62.20% 5.95% Compare
TFX Teleflex Incorporated $5.4B — (loss-making) 45.3× +28.88% (above 0%: growing) −17.33% (below 0%: shrinking) +220.14% (above 0%: growing) 58.16% 12.77% Compare
MMSI Merit Medical Systems, Inc. $5.4B 36.4× 23.4× +9.51% (above 0%: growing) +18.18% (above 0%: growing) −25.66% (below 0%: shrinking) 51.37% 14.42% Compare
STVN Stevanato Group S.p.A. $5.3B 33.8× 27.5× +10.46% (above 0%: growing) −25.00% (below 0%: shrinking) −167.02% (below 0%: shrinking) 28.75% 12.93% Compare
Median of peers $8.3B 33.8× 27.5× +9.30% −17.33% +46.53% 56.04% 12.85%

All 55 Medical Instruments & Supplies stocks →

AptarGroup, Inc. (ATR) key facts

  • Strength: AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024.
  • Strength: Net income was $392.5 million, or $5.97 per share (basic), a net margin of 10.4%.
  • AptarGroup, Inc. (ATR) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, ATR traded at $124.51, a market capitalization of $7.9 billion.
  • At that price the stock trades at 22.2× trailing-twelve-month earnings and 2.0× sales; its P/E is higher than 8% of its own readings over the past ten years.
  • AptarGroup, Inc. pays an annual dividend of $1.92 per share, a yield of 1.54%, with a payout ratio of 34.7%.
  • Return on equity was 15.2% and debt-to-equity 0.52.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.78 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

AptarGroup, Inc. (ATR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ATR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com